RPRD1B/CREPT facilitates the progression of diffuse large B-cell lymphoma by inhibiting apoptosis through the NF-κB signaling pathway

Abstract

Objective: To investigate the role of RPRD1B in the progression of diffuse large B-cell lymphoma (DLBCL) and its potential as a therapeutic target. Methods: This study analyzed RPRD1B expression in DLBCL and normal tissues using public databases and assessed its prognostic impact through survival analysis. In vitro and in vivo experiments were conducted to explore the mechanisms by which RPRD1B influences tumor growth and apoptosis. Results: RPRD1B expression was significantly elevated in DLBCL compared to normal tissues and was associated with poor prognosis. In vitro and in vivo experiments demonstrated that RPRD1B promoted lymphoma cell proliferation and inhibited apoptosis through the NF-κB signaling pathway. Conclusions: RPRD1B plays a critical role in the progression of DLBCL by modulating apoptosis and cellular proliferation. Targeting RPRD1B may offer a novel therapeutic strategy for DLBCL, suggesting its potential as a prognostic marker and therapeutic target in hematological malignancies.

Keywords

RPRD1B / RNAPⅡ / Diffuse large B-cell lymphoma / NF-κB / Apoptosis

Acknowledgments

The authors thank Weifeng Lu and Song Chen for their help in collecting and organizing data, and for assisting with financial reimbursement. They also sincerely acknowledge the TCGA and GEO databases for providing their platforms and the contributors for uploading meaningful datasets.

Conflict of interest statement

The authors declare no conflict of interest.

Funding

This research was funded by Hainan Provincial Natural Science Foundation of China (820QN401, 822QN468), Science and Technology Special Fund of Hainan Province, China, (ZDYF2024SHFZ114), Health Science and Technology Innovation Joint Project of Hainan Province, China (WSJK2024MS231), and Hainan Province Clinical Medical Center Construction (Project [2022]276).

Data availability statement

The data supporting the findings of this study are available from the corresponding authors upon request.

Authors’ contributions

LX designed the work, performed the experiments and wrote the original draft. ZHX conducted experiments and collected data. JL, ST and FLR established the experimental methods and conducted the experiments. YYW and ZJC supervised the project. XBH analyzed and interpreted the data and revised the manuscript. All authors have read and approved the final manuscript.

References

[1] Lu D, Wu Y, Wang Y, Ren F, Wang D, Su F, et al. CREPT accelerates tumorigenesis by regulating the transcription of cell-cycle-related genes. Cancer Cell 2012; 21(1): 92-104.

[2] Liu J, Liu H, Zhang X, Gao P, Wang J, Hu Z. Identification and characterization of P15RS, a novel P15INK4b-related gene on G₁/S progression . Biochem Biophys Res Commun 2002; 299(5). doi: 10.1016/S0006-291X(02)02684-0.

[3] Ni Z, Olsen JB, Guo X, Zhong G, Ruan ED, Marcon E, et al. Control of the RNA polymerase Ⅱ phosphorylation state in promoter regions by CTD interaction domain-containing proteins RPRD1A and RPRD1B. Transcription 2011; 2(5). doi: 10.4161/trns.2.5.17803.

[4] Ni Z, Xu C, Guo X, Hunter GO, Kuznetsova OV, Tempel W, et al. RPRD1A and RPRD1B are human RNA polymerase ⅡC-terminal domain scaffolds for Ser5 dephosphorylation. Nat Struct Mol Biol 2014; 21(8): 686-695.

[5] Liang J, Qiu Y, Wang Y, Ren F, Chang Z. CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome. Int J Clin Exp Pathol 2017; 10(2): 2030-2035.

[6] Yu S, Huang H, Wang S, Xu H, Xue Y, Huang Y, et al. CREPT is a novel predictor of the response to adjuvant therapy or concurrent chemoradiotherapy in esophageal squamous cell carcinoma. Int J Clin Exp Pathol 2019; 12(9): 3301-3310.

[7] Siril YJ, Kouketsu A, Saito H, Takahashi T, Kumamoto H. Immunohistochemical expression levels of cyclin D1 and CREPT reflect the course and prognosis in oral precancerous lesions and squamous cell carcinoma. Int J Oral Maxillofac Surg 2022; 51(1): 27-32.

[8] Ma J, Ren Y, Zhang L, Kong X, Wang T, Shi Y, et al. Knocking-down of CREPT prohibits the progression of oral squamous cell carcinoma and suppresses cyclin D1 and c-Myc expression. PLoS One 2017; 12(4). doi: 10.1371/journal.pone.0174309.

[9] Wei M, Cao Y, Jia D, Zhao H, Zhang L. CREPT promotes glioma cell proliferation and invasion by activating Wnt/β-catenin pathway and is a novel target of microRNA-596. Biochimie 2019; 162: 116-124.

[10] Yang G, Wang Y, Xiao J, Zhao F, Qiu J, Liu Y, et al. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. Cell Oncol 2021; 44(2): 345-355.

[11] Zhang Z, Shao L, Wang Y, Luo X. MicroRNA-501-3p restricts prostate cancer growth through regulating cell cycle-related and expression-elevated protein in tumor/cyclin D1 signaling. Biochem Biophys Res Commun 2019; 509(3): 746-752.

[12] Liu H, Seynhaeve ALB, Brouwer RWW, van IJcken WFJ, Yang L, Wang Y, et al. CREPT promotes melanoma progression through accelerated proliferation and enhanced migration by RhoA-mediated actin filaments and focal adhesion formation. Cancers (Basel) 2020; 12(1): 33.

[13] Wen N, Bian L, Gong J, Meng Y. Overexpression of cell-cycle related and expression-elevated protein in tumor (CREPT) in malignant cervical cancer. J Int Med Res 2020; 48(1). doi: 10.1177/0300060519895089.

[14] Li W, Zheng G, Xia J, Yang G, Sun J, Wang X, et al. Cell cycle-related and expression-elevated protein in tumor overexpression is associated with proliferation behaviors and poor prognosis in non-small-cell lung cancer. Cancer Sci 2018; 109(4): 1012-1023.

[15] Hyun MJ, Choi SJ, Jin KK. Expression profiles of SV40-immortalization-associated genes upregulated in various human cancers. J Cell Biochem 2009; 106(4): 703-713.

[16] Zheng G, Li W, Zuo B, Guo Z, Xi W, Wei M, et al. High expression of CREPT promotes tumor growth and is correlated with poor prognosis in colorectal cancer. Biochem Biophys Res Commun 2016; 480(3): 436-442.

[17] Liang Z, Feng Q, Xu L, Li S, Zhou L. CREPT regulated by miR-138 promotes breast cancer progression. Biochem Biophys Res Commun 2017; 493(1): 263-269.

[18] Jin K, Chen H, Zuo Q, Huang C, Zhao R, Yu X, et al. CREPT and p15RS regulate cell proliferation and cycling in chicken DF-1 cells through the Wnt/β-catenin pathway. J Cell Biochem 2018; 119(1): 1083-1092.

[19] Liu T, Li WM, Wang WP, Sun Y, Ni YF, Xing H, et al. Inhibiting CREPT reduces the proliferation and migration of non-small cell lung cancer cells by down-regulating cell cycle related protein. Am J Transl Res 2016; 8(5): 2097-2113.

[20] Jiang J, Yang X, He X, Ma W, Wang J, Zhou Q, et al. MicroRNA-449b-5p suppresses the growth and invasion of breast cancer cells via inhibiting CREPT-mediated Wnt/β-catenin signaling. Chem Biol Interact 2019; 302: 74-82.

[21] Sun M, Si G, Sun HS, Si FC. Inhibition of CREPT restrains gastric cancer growth by regulation of cycle arrest, migration and apoptosis via ROS-regulated p53 pathway. Biochem Biophys Res Commun 2018; 496(4): 1183-1190.

[22] Opinto G, Vegliante MC, Negri A, Skrypets T, Loseto G, Pileri SA, et al. The tumor microenvironment of DLBCL in the computational era. Front Oncol 2020; 10. doi: 10.3389/fonc.2020.00351.

[23] Imam S, Aijaz M, Iffat W, Jamshed SQ, Ismail NE, Paneerselvam GS, et al. Attitudes and understanding of complementary and alternative medicine in cancer care: An exploratory study of patients’ perspectives in Karachi, Pakistan. Asian Pac J Trop Med 2023; 16(9): 400-408.

[24] Tao S, Chen Y, Hu M, Xu L, Fu CB, Hao XB. LncRNA PVT1 facilitates DLBCL development via miR-34b-5p/Foxp1 pathway. Mol Cell Biochem 2022; 477(3): 951-963.

[25] Ren F, Wang R, Zhang Y, Liu C, Wang Y, Hu J, et al. Characterization of a monoclonal antibody against CREPT, a novel protein highly expressed in tumors. Monoclon Antib Immunodiagn Immunother 2014; 33(6). doi: 10.1089/mab.2014.0043.

[26] Rong Y, Cheng L, Ning H, Zou J, Zhang Y, Xu F, et al. Wilms’ tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: A possible mechanism in sporadic Wilms’ tumor. Cancer Res 2006; 66(16): 8049-8057.

[27] Yeh I, Motea EA, Boothman DA. Kub5-Hera RPRD1B regulates CDK1 expression through the DREAM complex. FASEB J 2019; 33(S1). doi: 10.1096/fasebj.2019.33.1_supplement.458.19.

[28] Wang Y, Qiu H, Hu W, Li S, Yu J. RPRD1B promotes tumor growth by accelerating the cell cycle in endometrial cancer. Oncol Rep 2014; 31(3): 1389-1395.

[29] Morales JC, Richard P, Rommel A, Fattah FJ, Motea EA, Patidar PL, et al. Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair. Nucleic Acids Res 2014; 42(8): 4996-5006.

[30] Patidar PL, Motea EA, Fattah FJ, Zhou Y, Morales JC, Xie Y, et al. The Kub5-Hera/RPRD1B interactome: A novel role in preserving genetic stability by regulating DNA mismatch repair. Nucleic Acids Res 2015; 44(4): 1718-1731.

[31] Karimaian A, Majidinia M, Bannazadeh Baghi H, Yousefi B. The crosstalk between Wnt/β-catenin signaling pathway with DNA damage response and oxidative stress: Implications in cancer therapy. DNA Repair 2017; 51: 14-19.

[32] Morana O, Wood W, Gregory CD. The apoptosis paradox in cancer. Int J Mol Sci 2022; 23(3). doi: 10.3390/ijms23031328.

[33] Pfeffer CM, Singh ATK. Apoptosis: A target for anticancer therapy. Int J Mol Sci 2018; 19(2). doi: 10.3390/ijms19020448.

[34] Polager S, Ginsberg D. NF-kappaB at the crossroads of life and death. Trends Cell Biol 2002; 3(3): 221-227.

[35] Zinatizadeh MR, Schock B, Chalbatani GM, Zarandi PK, Jalali SA, Miri SR. The nuclear factor kappa B (NF-κB) signaling in cancer development and immune diseases. Genes Dis 2021; 8(3): 287-297.

[36] Johansson P, Klein-Hitpass L, Grabellus F, Arnold G, Klapper W, Pförtner R, et al. Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas. Oncotarget 2016; 7(38): 62627-62639.

[37] Balaji S, Ahmed M, Lorence E, Yan F, Nomie K, Wang M. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma. J Hematol Oncol 2018; 11(1): 83. doi: 10.1186/s13045-018-0621-5.

[38] Creixell M, Kim H, Mohammadi F, Peyton SR, Meyer AS. Systems approaches to uncovering the contribution of environment-mediated drug resistance. Curr Opin Solid State Mater Sci 2022; 26(5). doi: 10.1016/j.cossms.2022.101005.

[39] Shen LL, Huang WH, Zhao HJ, Yuan XW. Dehydroabietic acid chemosensitizes drug-resistant acute lymphoblastic leukemia cells by downregulating survivin expression. Asian Pac J Trop Biomed 2022; 12(9): 383-390.

[40] Wang J, Xu Z, Lai Y, Zhang Y, Zhang P, Mu Q, et al. Anlotinib inhibiting mantle cell lymphoma proliferation and inducing apoptosis through PI3K/AKT/mTOR pathway. Curr Mol Med 2024. doi: 10.2174/0115665240284638240408081133.

[41] Sun X, Zhang R, Xu J, Xie L, Guo W. First line anlotinib plus liposomal doxorubicin for locally advanced or metastatic soft tissue sarcoma: A prospective, single-arm trial. Asian Pac J Trop Med 2022; 15(6): 266-273.